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The genus Chryseobacterium and other genera belonging to the family Flavobacteriaceae include organisms
that can behave as human pathogens and are known to cause different kinds of infections. Several species of
Flavobacteriaceae, including Chryseobacterium indologenes, are naturally resistant to -lactam antibiotics (in-
cluding carbapenems), due to the production of a resident metallo--lactamase. Although C. indologenes
presently constitutes a limited clinical threat, the incidence of infections caused by this organism is increasing
in some settings, where isolates that exhibit multidrug resistance phenotypes (including resistance to amino-
glycosides and quinolones) have been detected. Here, we report the identification and characterization of a new
IND-type variant from a C. indologenes isolate from Burkina Faso that is resistant to -lactams and amin-
oglycosides. The levels of sequence identity of the new variant to other IND-type metallo--lactamases range
between 72 and 90% (for IND-4 and IND-5, respectively). The purified enzyme exhibited N-terminal hetero-
geneity and a posttranslational modification consisting of the presence of a pyroglutamate residue at the N
terminus. IND-6 shows a broad substrate profile, with overall higher turnover rates than IND-5 and higher
activities than IND-2 and IND-5 against ceftazidime and cefepime.
Metallo--lactamases (MBLs) belong to Ambler’s class B,
and their activity requires at least one zinc ion in the active site.
These enzymes are particularly worrisome resistance determi-
nants due to their ability to hydrolyze most -lactam com-
pounds, including carbapenems, while they are not susceptible
to conventional -lactamase inhibitors (e.g., clavulanic acid,
sulbactam, and tazobactam) (25). Besides the acquired MBL
genes which currently disseminate in major human pathogens
(e.g., Pseudomonas aeruginosa) by means of mobile genetic
elements (plasmids, integrons, or ISCR elements), most MBL
genes identified thus far have been found in the chromosomes
of various bacterial species, including nonpathogenic organ-
isms (such as Caulobacter crescentus), plant pathogens (Erwinia
carotovora), and occasional human pathogens such as Stenotro-
phomonas maltophilia, Aeromonas spp., and members of the
family Flavobacteriaceae (25, 32). The latter family includes
several species in which the production of a resident MBL has
been detected. Although their overall clinical impact is lower
than that of Enterobacteriaceae, Pseudomonas, or Acinetobacter
species, Flavobacteriaceae may cause various clinical syn-
dromes that are not always straightforward to treat, due mainly
to their intrinsic resistance to several antimicrobial agents (29).
Eight different sublineages of resident enzymes in members of
the family Flavobacteriaceae have been identified thus far (4–7,
18, 20, 26), and most of them (BlaB from Elizabethkingia me-
ningoseptica, IND from Chryseobacterium indologenes, JOHN
from Flavobacterium johnsoniae, CGB from Chryseobacterium
gleum, EBR from Empedobacter brevis, TUS from Myroides
odoratus, and MUS from Myroides odoratimimus) belong to
subclass B1, although the GOB enzymes (from E. meningosep-
tica) belong to subclass B3.
The most common flavobacterium from clinical specimens is
C. indologenes, which is associated with different types of in-
fections, such as intra-abdominal and urinary tract infections,
catheter-related bacteremia, cellulitis, sepsis, and pneumonia,
likely promoted by the bacterium’s ability to form biofilm and
to produce proteases (1, 3, 15, 16, 21, 23, 24, 33). In some
nosocomial settings, C. indologenes infections were also asso-
ciated with relatively high mortality rates (16). Six variants of
resident MBLs (IND-1 to IND-5 and IND-2a) have been de-
tected in C. indologenes, and these variants diverge by at most
27% (IND-2a versus IND-4) at the protein sequence level (6,
8, 22). The biochemical characterization of these enzymes re-
vealed interesting functional differences regarding affinities for
various substrates, turnover rates (with up to 30-fold variation
between the rates of two variants for the same substrate), and
their abilities to hydrolyze ceftazidime or cefepime (8, 22). In
this work, we report the isolation of a C. indologenes strain
from Burkina Faso that caused a urinary tract infection and
produces a new IND-type variant, named IND-6, for which
detailed biochemical characterization was performed.
MATERIALS AND METHODS
Bacterial strains and culture conditions. C. indologenes strain 597 was ob-
tained from a urine sample from an outpatient at the Saint Camille Medical
Center, Ouagadougou, Burkina Faso (34), and was used as the source of the
MBL gene. Escherichia coli DH5 (Gibco Life Technologies, Gaithersburg, MD)
was used as a host for recombinant plasmids, while E. coli BL21(DE3) (Strat-
* Corresponding author. Mailing address: Dipartimento di Biologia
Molecolare, Universita` di Siena, Policlinico Le Scotte, I-53100 Siena,
Italy. Phone: 39 0577 233134. Fax: 39 0577 233870. E-mail: jddocquier
@unisi.it.
 Published ahead of print on 3 August 2009.
4320
agene, La Jolla, CA) was used for overproduction of the IND-6 enzyme by a T7
promoter-based expression system. Bacteria were always grown aerobically. C.
indologenes and E. coli DH5 derivative strains were cultured at 37°C in Mueller-
Hinton broth (Oxoid Ltd., Basingstoke, United Kingdom). ZYP-0.8G medium
was used for routine propagation of E. coli BL21(DE3) derivatives, while ZYP-
5052 medium was used for production of the recombinant protein (30).
Molecular and recombinant DNA methodologies. The complete sequence of
the MBL gene from C. indologenes 597 was obtained using an inverse PCR
approach, as described previously by Bellais and coworkers (8). Genomic DNA
was obtained using the standard alkaline-sodium dodecyl sulfate lysis method
(27), and a 4-g sample was digested with restriction endonucleases BamHI,
ClaI, PstI, and SalI. After complete digestion, restriction fragments were circu-
larized by the addition of 1 U of T4 DNA ligase in the buffer system supplied by
the manufacturer (Roche Biochemicals, Mannheim, Germany). PCR was then
carried out as described previously (8) using circularized restriction fragments
from genomic DNA as the template, primers IND-INV/ (5-TTGGCAGAAT
ATTCTTTACC) and IND-INV/ (5-GAAAAAAGACGGAAAAGCAAC),
and 3 U of TTh DNA polymerase (Promega, Carlsbad, CA). The resulting
amplified fragments were cloned into plasmid pMOSBlue (GE Healthcare, Upp-
sala, Sweden), and both strands were sequenced using T7 promoter and M13 to
M20 universal primers (27).
The blaIND-6 open reading frame (ORF) was subsequently amplified by PCR
with a primer (5-GGGCATATGAAAAGAAGAATTCAGTTC) that added an
NdeI restriction site (underlined) to the 5 end and primer IND-EXP/r (5-CC
GGATCCTTATTATTTCTTATCCAGCAGC), which added a BamHI restric-
tion site (underlined) to the 3 end of the gene. PCR was performed with 5 U of
the Expand high-fidelity PCR system DNA polymerase in accordance with the
instructions of the manufacturer (Roche Biochemicals) by using 200 M de-
oxynucleoside triphosphates, 50 pmol of each primer, and 100 ng of C. indolo-
genes 597 genomic DNA as the template in a total volume of 50 l. Cycling
conditions were as follows: an initial denaturation step at 96°C for 3 min, 30
cycles of denaturation at 96°C for 40s, annealing at 53°C for 40 s, and extension
at 72°C for 2 min, and a final extension step at 72°C for 20 min. The amplified
DNA was cloned into vector pLB-II (a derivative of pBC-SK [Stratagene, La
Jolla, CA] modified in our laboratory) (9), yielding recombinant plasmid pLBII-
IND-ZB. After confirmatory sequencing, the 720-bp NdeI-BamHI fragment was
subcloned into the expression vector pET-9a (Novagen, Madison, WI) to obtain
recombinant plasmid pET9-IND-ZB.
Antimicrobial susceptibility testing. The in vitro antimicrobial susceptibility
profiles of C. indologenes 597 and E. coli DH5 derivatives were determined by
the broth microdilution method as recommended by the Clinical and Laboratory
Standards Institute (CLSI) (10) by using Mueller-Hinton broth with a bacterial
inoculum of 5  104 CFU/well. MICs were recorded after 18 h at 37°C.
Production and purification of IND-6. The cloned MBL of C. indologenes was
purified from a culture of E. coli BL21(DE3)(pET-IND-ZB) grown for 24 h at
37°C in 1 liter of ZYP-5052 medium supplemented with 50 g/ml kanamycin.
The culture supernatant, containing most of the -lactamase activity, was clari-
fied by centrifugation (10,000  g for 30 min at 4°C), concentrated using an
Amicon 2000 ultrafiltration device equipped with a YM10 membrane (Millipore,
Bedford, MA), and desalted using a HiPrep 26/10 desalting column (GE Health-
care, Uppsala, Sweden) and a solution of 10 mM HEPES-NaOH containing 50
M ZnSO4 (pH 7.5; HZN buffer) as the elution buffer. The resulting sample was
loaded at a flow rate of 2 ml/min onto an SP Sepharose high-performance
column (bed volume, 5 ml; GE Healthcare), and bound proteins were eluted
using a linear NaCl gradient (0 to 1 M in 100 ml). The -lactamase-containing
fractions were diluted 10-fold in 10 mM MES (morpholineethanesulfonic acid)
buffer (pH 6.0) supplemented with 50 M ZnSO4 and loaded onto a Resource
S column (bed volume, 1 ml) preequilibrated with the same supplemented buffer.
Bound proteins were eluted using a linear NaCl gradient in the same buffer (0 to
0.5 M in 25 ml), and -lactamase-containing fractions were pooled, concentrated
to 0.25 mg/ml, and stored at 20°C until further use.
Protein analysis techniques. Sodium dodecyl sulfate-polyacrylamide gel elec-
trophoresis analysis, isoelectric focusing, and determination of protein concen-
trations in solution were performed as described previously (11). The molecular
mass of the native IND-6 enzyme was estimated by size exclusion chromatogra-
phy using a Superdex 75 HR 10/30 column (GE Healthcare) with HZN buffer
supplemented with 150 mM NaCl as described previously (11). Electrospray
ionization mass spectrometry analysis of the purified enzyme (final concentra-
tion, 15 M) was carried out using a quadrupole time of flight (TOF) Ultima
mass spectrometer (Micromass, Manchester, United Kingdom) equipped with a
nanospray source, as described previously (12). Peptide mass fingerprint analysis
was performed after digestion of the protein sample with either trypsin or ArgC
endoproteinase by using an Ultraflex II TOF/TOF mass spectrometer (Bruker
Daltonics, Bremen, Germany). Resulting data were analyzed with Biotools 3.0
software (Bruker Daltonics). The putative structure of IND-6 was computed
using the homology modeling service available at the ExPASy/SwissProt website
(Swiss-Model Workspace [http://swissmodel.expasy.org/workspace/]) with the
crystal structure of BlaB1 (Protein Data Bank code 1M2X) as the starting model
(2, 14).
Determination of kinetics parameters and inactivation by chelating agents.
The hydrolysis of -lactam substrates was monitored by measuring the absor-
bance variation under the experimental conditions reported previously (11). All
measurements were performed with a Cary 100 UV-vis spectrophotometer (Var-
ian, Walnut Creek, CA) or an Uvikon XL spectrophotometer (Kontron Instru-
ments, Eching, Germany) at 30°C using HZN buffer in a reaction volume of 500
l. Purified IND-6 was diluted in HZN buffer supplemented with 20 g/ml
bovine serum albumin to prevent enzyme denaturation. The steady-state kinetic
parameters (kcat and Km) were calculated after direct fitting of the initial rates to
the Henri-Michaelis-Menten equation or with the use of Hanes-Woolf linear-
ization. The inactivation of IND-6 by EDTA and pyridine-2,6-dicarboxylic (di-
picolinic) acid at 30°C in 50 mM HEPES buffer (pH 7.5) was studied using 150
M imipenem as the reporter substrate. Kinetic parameters of inactivation were
computed as described previously (11).
Nucleotide sequence accession number. The nucleotide sequence determined
in this study has been submitted to the EMBL/GenBank/DDBL sequence data-
bases and assigned the accession number AM087455.
RESULTS AND DISCUSSION
Susceptibility profile of and -lactamase production in C.
indologenes 597. The C. indologenes 597 isolate was recovered
from a urine sample from a 25-year-old female outpatient at
the Saint Camille Hospital Centre in Ouagadougou, Burkina
Faso. No evidence of previous antibiotic treatments was re-
corded. Determination of the antimicrobial susceptibility pro-
file showed that C. indologenes 597 was resistant to several
-lactam agents, including ampicillin, amoxicillin (amoxicil-
line)-clavulanic acid, cephalothin (cefalotin), cefuroxime, and
imipenem (MICs, 64 g/ml), and notably to all tested ami-
noglycosides (amikacin MIC, 64 g/ml; gentamicin and to-
bramycin MICs,16 g/ml). The strain also showed decreased
susceptibilities to cefoxitin, cefotaxime, and meropenem
(MICs, 16, 32, and 8 g/ml, respectively), while it was suscep-
tible to piperacillin, piperacillin-tazobactam, ceftazidime,
cefepime, all tested quinolones (ciprofloxacin, norfloxacin, and
ofloxacin [MICs,2 g/ml]), and a folate metabolism inhibitor
(trimethoprim-sulfamethoxazole) (Table 1). Hydrolysis tests
performed with various -lactam substrates (including ampi-
cillin, cephalothin, cefotaxime, and imipenem) and a crude
extract of C. indologenes 597 demonstrated the production of a
-lactamase, the activity of which could be inhibited 95%
after incubation with 5 mM EDTA, indicating the production
of an MBL most likely of the IND type. Nitrocefin hydrolysis
after isoelectric focusing revealed the presence of a single
-lactamase band at pI 9.0, suggesting that other -lactamases,
including serine-active enzymes, were not produced at a sig-
nificant level by this strain.
Molecular cloning of blaIND-6, a new IND-type MBL variant.
Due to sequence heterogeneity at the 5 and 3 extremities of
the MBL gene, direct amplification with consensus primers
designed to amplify all known IND-like MBL genes (blaIND-1
to blaIND-5) was unsuccessful. On that basis, the inverse PCR
approach was adopted to obtain the complete sequence of the
blaIND-like ORF, as done previously by Bellais and coworkers
(8). By using circularized restriction fragments of genomic
DNA as the template in the PCR, an amplification fragment
(approximately 1 kb) was obtained from the samples digested
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with the ClaI restriction endonucleases and was cloned into
plasmid pMOSBlue to yield recombinant vector pIND-597.
Sequencing of the cloned PCR fragment allowed the determi-
nation of the nucleotide sequence of the whole blaIND-like
ORF (723 bp) and approximately 300 bp of the upstream
flanking region.
The product of the blaIND ORF showed the highest se-
quence similarities to IND-1, IND-3, and IND-5 variants
(identity scores computed using the complete protein sequence
ranged from 88.3 to 89.5%) but also showed 11 unique substi-
tutions, thus constituting a new IND variant, named IND-6
(Fig. 1 and 2), that also increases the maximum sequence
divergence among IND-type variants (to 28.5%, between
IND-4 and IND-6). Of these 11 unique substitutions, 10 were
located in the mature protein and most were concentrated in
the N-terminal domain between Asp-120 and His-196 (Pro-
140, Gln-144, Arg-148, Pro-176, and Phe-182) or in the C-
terminal domain between Cys-221 and His-263 (Leu-239, His-
247, Glu-255, and Val-257) (Fig. 1 and 3).
No other putative ORFs could be found immediately up-
stream of the blaIND-6 ORF, as reported previously (6, 8),
although comparison of the available 300-bp nucleotide se-
quence with the sequence found upstream of the blaIND-1 gene
showed significant heterogeneity (identity, 71%), and compar-
ison with the sequence upstream of the blaCGB gene also
showed some extent of heterogeneity. Another difference con-
cerns the nature of the putative promoter found upstream of
the MBL gene, which possesses a mutation in the 35 signal
(ttGcta, where the uppercase letter indicates the position of
the mutation) compared to the 35 promoter sequence found
upstream of the blaIND-1 gene (ttCcta) and may explain, in
addition to individual catalytic features of the various IND-
type enzymes, the different levels of intrinsic resistance to
-lactams exhibited by various C. indologenes strains, as re-
ported recently (17).
After subcloning of the blaIND-6 ORF into a proper vector
system (i.e., one carrying a resistance marker other than am-
picillin resistance), which was introduced into E. coli, the an-
timicrobial susceptibility profile of the host was determined,
showing that the production of IND-6 resulted in increased
MICs of all tested antibiotics except aztreonam, which is not a
substrate for MBLs (Table 1). The production of IND-6 in E.
coli did not confer resistance (according to CLSI breakpoints)
to carbapenem antibiotics (10). These data are in agreement
with those reported for E. coli laboratory strains producing
other MBL determinants (4–8, 18, 20, 22, 26) and should be
related to the fast permeation of these agents into the host, as
demonstrated previously (19).
Purification and biophysical characterization of IND-6. The
MBL was successfully produced by the strategy adopted for the
production of other MBLs (11, 12), i.e., using a T7 promoter-
TABLE 1. In vitro susceptibility profiles of C. indologenes 597,
E. coli DH5(pLBII-IND-ZB) carrying the cloned blaIND-6













Piperacillin 4 ND ND
Piperacillin-tazobactam 4 ND ND
Ticarcillin ND 256 4
Temocillin ND 16 4
Cephalothin 64 64 4
Cefoxitin 16 16 2
Cefuroxime 64 32 2
Cefotaxime 32 0.5 0.12
Ceftazidime 8 1 0.12
Cefepime 1 0.12 0.03
Ceftriaxone ND 0.12 0.03
Imipenem 64 1 0.12
Meropenem 8 0.12 0.03
Aztreonam ND 0.25 0.25
a ND, not determined.






kcat/Km value (M1 s1) for:
IND-6 IND-2 IND-5 BlaB1
Benzylpenicillin 305 20 1.5  107 4.6  106 8.4  105 2.7  107
Amoxicillin 480 85 5.6  106 b  
Carbenicillin 210 30 7.0  106  5.3  104 6.1  106
Cephalothin 415 60 6.9  106 1.2  106  1.6  106
Cephaloridine 490 90 5.4  106   1.4  105
Cephalexin 19 3 6.3  106   
Cefuroxime 75 23 3.3  106   1.0  106
Cefotaxime 8 33 2.4  105 9.0  105 3.1  104 7.9  105
Ceftazidime 6 22 2.7  105 4.5  103 NDd,e 6.6  103
Cefepime 1.2 300 4.0  103 4.5  102 NDd,e 2.0  102
Nitrocefin 115 43 2.7  106   3.9  106
Imipenem 50 13 3.8  106 5.9  105 2.4  104 2.0  106
Meropenem 25 145 1.7  105 1.8  105 1.5  104 7.6  105
Aztreonam NHc NDd NDd NDd NDd NDd
a Standard deviations were below 10%. kcat/Km values for IND-2, IND-5, and BlaB1 are shown for comparison (8, 22, 26).
b , data not available.
c NH, no hydrolysis detected with enzyme concentrations up to 0.9 M.
d ND, not determined.
e Ceftazidime and cefepime are not hydrolyzed by IND-5 (22).
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based E. coli expression system, which yielded approximately 2
mg of recombinant protein per liter of culture. The purification
scheme involved two chromatographic steps and yielded an
enzyme preparation with a purity of 95%, with a global yield
of approximately 25% (this apparently low yield from the pu-
rification protocol is explained by the fact that only the purest
fractions were kept for subsequent analysis). The apparent
molecular mass of the enzyme in solution (Mr 	 25,000 

5,000) determined by size exclusion chromatography indicated
that the enzyme in solution is monomeric. Electrospray ion-
ization mass spectrometry analysis of the purified sample re-
vealed the presence of four distinct enzyme species (corre-
sponding to masses of 24,707.4, 24,725.9, 24,794.0, and
24,882.6 Da; standard deviation, 3 Da), suggesting the pres-
ence of either amino- or carboxy-terminal heterogeneity or
other kinds of posttranslational modifications. Peptide mass
fingerprint and matrix-assisted laser desorption ionization–
TOF mass spectrometry analyses revealed that peptides show-
ing mass heterogeneity could be assigned to the N-terminal
extremity of the protein. The higher-mass species, which rep-
resented only a minor isoform, corresponded to the mature
protein obtained by cleavage of an 18-residue signal peptide
(theoretical mass, 24,884.5 Da), while two lower-mass species
(24,794.0 and 24,725.9 Da) corresponded to alternative cleav-
age sites after positions 19 and 20, respectively. These three
forms thus correspond to the deduced N-terminal sequences
S19AQVK, A20QVKD, and Q21VKDF. The lowest-mass spe-
cies, presenting an additional loss of 18 mass units, was attrib-
uted to the cyclization of the N-terminal glutamine to form a
pyroglutamate residue. This posttranslational modification is
common in proteins and may have biological implications, as
proteins bearing an N-terminal pyroglutamate residue exhibit
greater stability against proteolysis (28).
Biochemical features of IND-6. The purified enzyme hydro-
lyzed all the tested -lactam substrates (except aztreonam),
showing a broad substrate profile (Table 2). The highest
kcat/Km values were observed with penicillins, narrow-spectrum
cephalosporins, cefuroxime, and imipenem (kcat/Km values,
106 M1  s1). Cefotaxime, ceftazidime, and meropenem
were roughly 50- to 90-fold less reactive than benzylpenicillin.
Cefepime behaved as the worst substrate, although the ob-
served kcat/Km values were higher than those measured with
other IND variants (i.e., IND-2 and IND-5, for which kinetic
parameters have been measured) or with BlaB1 (8, 22, 26).
The latter was also true for ceftazidime, which showed a 60-
fold-higher kcat/Km value with IND-6 than with IND-2 (4,500
FIG. 1. Alignment of multiple amino acid sequences from IND variants (IND-1 [accession no. AAD20273], IND-2 [accession no. AAG29757],
IND-2a [accession no. AAG29760], IND-3 [accession no. AAG29762], IND-4 [accession no. AAG29765], and IND-5 [accession no. AAS78754]).
The new IND variant from C. indologenes 597 exhibits the closest relationship with IND-5 (89.5% pairwise sequence identity), while being more
divergent from IND-4 (71.5% identity). The standard numbering scheme for class B -lactamases has been used (13). Identical residues are shaded
in gray, and the conserved zinc-binding residues of subclass B1 MBLs are shaded in black. Unique substitutions found in IND-6 are boxed.
FIG. 2. Unrooted tree showing the phylogenetic relationships of
IND-6 with other MBLs identified in bacterial species belonging to the
family Flavobacteriaceae (accession numbers of sequences are as given
in the legend to Fig. 1).
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M1  s1), while this substrate was not recognized by IND-5
(8, 22).
The highest turnover rates were observed with penicillins
and narrow- and expanded-spectrum cephalosporins (kcat val-
ues, 75 s1), except for cephalexin (cefalexin), which inter-
estingly showed a much lower kcat value than cephalothin or
cephaloridine (Table 2). This finding likely reflects the pres-
ence of an amino group on the C-7 side chain and the absence
of a leaving group on the C-3 carbon, which would be respon-
sible for slower hydrolysis of this compound (Fig. 4). IND-6
also exhibited lower Km values for ceftazidime, imipenem, and
meropenem than other IND variants, indicating better recog-
nition of these substrates. Overall, IND-6 exhibited functional
properties that are very different from those of IND-5, despite
the fact that these two enzymes share 90% amino acid se-
quence identity, as summarized by the higher reactivity of
IND-6 toward ceftazidime and cefepime (which are not hydro-
lyzed by IND-5) and overall much higher turnover rates. These
results may further support the hypothesis that the substitution
E265D occurring in IND-5 may be detrimental for the hydro-
lysis of some substrates (22). Position 265 is located only one
residue away from the zinc-binding His-263 residue, and it may
be hypothesized that a substitution in the loop where the latter
residue is found may influence the position of its side chain,
possibly inducing subtle changes in the geometry of the zinc-2
site and thus the activity of the enzyme. The potential effect of
remote mutations on enzyme activity was already described for
another model enzyme (31). Interestingly, the same substitu-
tion (E265D) is also found in the BlaB1 enzyme, which also
shows lower catalytic efficiencies with ceftazidime and
cefepime. Nevertheless, it is likely that substitutions other than
E265D are responsible for the overall properties of IND-6, as
reflected by the fact that IND-2, which does not exhibit the
E265D substitution, also shows differences from IND-6 in
terms of catalytic efficiencies with some substrates.
In inactivation experiments, IND-6 showed greater suscep-
FIG. 3. Cartoon representation of the IND-6 homology model showing the putative tertiary structure and the locations of amino acid
substitutions discussed in the text. The positions of unique substitutions found in IND-6 are shown as black spheres; the position of residue E265,
located close to the active-site residue H263 and replaced with aspartate in IND-5 and BlaB1, is also shown.
FIG. 4. Comparison of the structures of cephalothin (cefalotin) (a)
and cephalexin (cefalexin) (b), showing the nonreplaced methyl group
at the 3 position and the presence of an amino group on the side chain
at the 7 position in the latter.
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tibility to dipicolinic acid than to EDTA. As observed for other
subclass B1 MBLs (11, 25), the inactivation rates varied pro-
portionally with the inactivator concentration and only the
pseudo-first-order constant, which reflects the inactivation ef-
ficiency, could be determined (k2/K values, 9.4 and 170
M1  s1 for EDTA and dipicolinic acid, respectively, where
k2 is the individual rate constant for the dissociation of the
ternary Zn-enzyme-chelator complex into the apoenzyme and
the metal-chelator complex and K is the dissociation constant
of the ternary complex in the model proposed by Hernandez-
Valladeres et al. [15a]). These values were similar to those
observed with other subclass B1 enzymes (11, 25).
Concluding remarks. C. indologenes is increasingly reported
to be a fastidious organism, involved in many different types of
infections. Its intrinsic resistance to most -lactam agents, in-
cluding carbapenems, and occasional association with resis-
tance to aminoglycosides and fluoroquinolones may limit the
available options for successful antimicrobial treatment (18).
In this work, we described the new resident MBL determinant
IND-6, identified in an isolate from Burkina Faso, which
showed particularly high hydrolytic activities against -lactam
substrates. The apparent contrast between the catalytic prop-
erties of the enzyme and the antimicrobial susceptibility profile
of the original host (which showed susceptibility to ceftazidime
and cefepime and only intermediate resistance to meropenem)
most likely results from a low level of expression of the MBL
determinant. This variability in the resistance pattern has also
recently been observed between strains producing identical
MBL determinants (namely, IND-1 or IND-2), supporting the
idea that alterations in the promoter sequence may influence
the resistance level (18). In addition, differences in the perme-
ability of the outer membrane or the sensitivity of the penicil-
lin-binding proteins may be factors in resistance (although
these issues have not been specifically investigated in the
present study), as hypothesized previously and in agreement
with the fact that C. indologenes isolates commonly exhibit
resistance to aztreonam, which is not a substrate of MBLs (18).
Should this species be more and more frequently encountered
in the clinical setting, the questions of (i) whether -lactams
could be successfully used against susceptible strains and (ii)
whether the apparently variable susceptibility profile would
rely on the acquisition of another resistance mechanism(s)
would deserve attention. Finally, the sequence heterogeneity
shown by IND-type enzymes, which leads to natural variants
showing different biochemical properties, makes these en-
zymes interesting models to investigate the role of remote
mutations in MBL structure and function.
ACKNOWLEDGMENTS
We thank Colette Duez and Andre´ Piette (Centre for Protein En-
gineering, University of Lie`ge, Belgium) for their excellent technical
assistance and helpful discussions. We also acknowledge the contribu-
tion of Pierette Melin (Medical Microbiology, University Teaching
Hospital, University of Lie`ge, Belgium).
This work was funded in part by grants from the Belgian Fonds
National de la Recherche Scientifique (F.R.S.-F.N.R.S.; FRFC grant
no. 2.4511.06) and the European Union (contract no. HPRN-CT-2002-
00264) and by the Belgian Coope´ration Universitaire au De´veloppe-
ment (CUD) Programme in partnership with the University of Oua-
gadougou, Burkina Faso.
REFERENCES
1. Akay, M., E. Gunduz, and Z. Gulbas. 2006. Catheter-related bacteremia due
to Chryseobacterium indologenes in a bone marrow transplant recipient. Bone
Marrow Transplant. 37:435–436.
2. Arnold, K., L. Bordoli, J. Kopp, and T. Schwede. 2006. The SWISS-MODEL
workspace: a web-based environment for protein structure homology mod-
elling. Bioinformatics 22:195–201.
3. Bayraktar, M. R., E. Aktas, Y. Ersoy, A. Cicek, and R. Durmaz. 2007.
Postoperative Chryseobacterium indologenes bloodstream infection caused by
contamination of distillate water. Infect. Control Hosp. Epidemiol. 28:368–
369.
4. Bellais, S., D. Aubert, T. Naas, and P. Nordmann. 2000. Molecular and
biochemical heterogeneity of class B carbapenem-hydrolyzing -lactamases
in Chryseobacterium meningosepticum. Antimicrob. Agents Chemother. 44:
1878–1886.
5. Bellais, S., D. Girlich, A. Karim, and P. Nordmann. 2002. EBR-1, a novel
Ambler subclass B1 -lactamase from Empedobacter brevis. Antimicrob.
Agents Chemother. 46:3223–3227.
6. Bellais, S., S. Leotard, L. Poirel, T. Naas, and P. Nordmann. 1999. Molecular
characterization of a carbapenem-hydrolyzing -lactamase from Chryseobac-
terium (Flavobacterium) indologenes. FEMS Microbiol. Lett. 171:127–132.
7. Bellais, S., T. Naas, and P. Nordmann. 2002. Genetic and biochemical
characterization of CGB-1, an Ambler class B carbapenem-hydrolyzing
-lactamase from Chryseobacterium gleum. Antimicrob. Agents Chemother.
46:2791–2796.
8. Bellais, S., L. Poirel, S. Leotard, T. Naas, and P. Nordmann. 2000. Genetic
diversity of carbapenem-hydrolyzing metallo--lactamases from Chryseobac-
terium (Flavobacterium) indologenes. Antimicrob. Agents Chemother. 44:
3028–3034.
9. Borgianni, L., J. M. Frere, G. M. Rossolini, and J. D. Docquier. 2006.
Mutational analysis of the VIM-2 active site: role of positions 64 and 87 in
enzyme activity and stability, abstr. C1-28, p. 63–64. Abstr. 46th Intersci.
Conf. Antimicrob. Agents Chemother., San Francisco, CA.
10. Clinical and Laboratory Standards Institute. 2006. Methods for dilution
antimicrobial susceptibility tests for bacteria that grow aerobically. Approved
standard, 7th ed. CLSI document M7–A7. Clinical and Laboratory Standards
Institute, Wayne, PA.
11. Docquier, J. D., J. Lamotte-Brasseur, M. Galleni, G. Amicosante, J. M.
Frere, and G. M. Rossolini. 2003. On functional and structural heterogeneity
of VIM-type metallo--lactamases. J. Antimicrob. Chemother. 51:257–266.
12. Docquier, J. D., F. Pantanella, F. Giuliani, M. C. Thaller, G. Amicosante, M.
Galleni, J. M. Frere, K. Bush, and G. M. Rossolini. 2002. CAU-1, a subclass
B3 metallo--lactamase of low substrate affinity encoded by an ortholog
present in the Caulobacter crescentus chromosome. Antimicrob. Agents Che-
mother. 46:1823–1830.
13. Galleni, M., J. Lamotte-Brasseur, G. M. Rossolini, J. Spencer, O. Dideberg,
and J. M. Frere. 2001. Standard numbering scheme for class B -lactamases.
Antimicrob. Agents Chemother. 45:660–663.
14. Garcia-Saez, I., J. Hopkins, C. Papamicael, N. Franceschini, G. Amicosante,
G. M. Rossolini, M. Galleni, J. M. Frere, and O. Dideberg. 2003. The 1.5-Å
structure of Chryseobacterium meningosepticum zinc -lactamase in complex
with the inhibitor, D-captopril. J. Biol. Chem. 278:23868–23873.
15. Green, B. T., and P. E. Nolan. 2001. Cellulitis and bacteraemia due to
Chryseobacterium indologenes. J. Infect. 42:219–220.
15a.Hernandez-Valladeres, M., A. Felici, G. Weber, H. W. Adolph, M. Zeppeza-
uer, G. M. Rossolini, G. Amicosante, J. M. Frere, and M. Galleni. 1997.
Zn(II) dependence of the Aeromonas hydraphila AE036 metallo--lactamase
activity and stability. Biochemistry 36:11534–11541.
16. Hsueh, P. R., L. J. Teng, P. C. Yang, S. W. Ho, W. C. Hsieh, and K. T. Luh.
1997. Increasing incidence of nosocomial Chryseobacterium indologenes in-
fections in Taiwan. Eur. J. Clin. Microbiol. Infect. Dis. 16:568–574.
17. Lin, X. H., Y. H. Xu, J. Cheng, T. Li, and Z. X. Wang. 2008. Heterogeneity
of blaIND metallo--lactamase-producing Chryseobacterium indologenes iso-
lates detected in Hefei, China. Int. J. Antimicrob. Agents 32:398–400.
18. Mammeri, H., S. Bellais, and P. Nordmann. 2002. Chromosome-encoded
-lactamases TUS-1 and MUS-1 from Myroides odoratus and Myroides odo-
ratimimus (formerly Flavobacterium odoratum), new members of the lineage
of molecular subclass B1 metalloenzymes. Antimicrob. Agents Chemother.
46:3561–3567.
19. Matsumura, N., S. Minami, Y. Watanabe, S. Iyobe, and S. Mitsuhashi. 1999.
Role of permeability in the activities of -lactams against gram-negative
bacteria which produce a group 3 -lactamase. Antimicrob. Agents Chem-
toher. 43:2084–2086.
20. Naas, T., S. Bellais, and P. Nordmann. 2003. Molecular and biochemical
characterization of a carbapenem-hydrolysing -lactamase from Flavobacte-
rium johnsoniae. J. Antimicrob. Chemother. 51:267–273.
21. Pan, H. J., L. J. Teng, Y. C. Chen, P. R. Hsueh, P. C. Yang, S. W. Ho, and
K. T. Luh. 2000. High protease activity of Chryseobacterium indologenes
isolates associated with invasive infection. J. Microbiol. Immunol. Infect.
33:223–226.
22. Perilli, M., B. Caporale, G. Celenza, C. Pellegrini, J. D. Docquier, M. Mez-
VOL. 53, 2009 IND-6 METALLO--LACTAMASE 4325
zatesta, G. M. Rossolini, S. Stefani, and G. Amicosante. 2007. Identification
and characterization of a new metallo--lactamase, IND-5, from a clinical
isolate of Chryseobacterium indologenes. Antimicrob. Agents Chemother.
51:2988–2990.
23. Ray, P., K. Sharma, and V. Gautam. 2005. Chryseobacterium indologenes
bacteremia: a case report. J. Commun. Dis. 37:259–260.
24. Reynaud, I., V. Chanteperdrix, C. Broux, P. Pavese, J. Croize, M. Maurin, J. P.
Stahl, and C. Jacquot. 2007. A severe form of Chryseobacterium indologenes
pneumonia in an immunocompetent patient. Med. Mal. Infect. 37:762–764.
25. Rossolini, G. M., and J. D. Docquier. 2007. Class B -lactamases, p. 115–144.
In R. A. Bonomo and M. E. Tolmasky (ed.), Enzyme-mediated resistance to
antibiotics: mechanisms, dissemination, and prospects for inhibition. ASM
Press, Washington, DC.
26. Rossolini, G. M., N. Franceschini, M. L. Riccio, P. S. Mercuri, M. Perilli, M.
Galleni, J. M. Frere, and G. Amicosante. 1998. Characterization and se-
quence of the Chryseobacterium (Flavobacterium) meningosepticum carbap-
enemase: a new molecular class B -lactamase showing a broad substrate
profile. Biochem. J. 332(Pt. 1):145–152.
27. Sambrook, J., and D. W. Russell. 2001. Molecular cloning: a laboratory
manual, 3rd ed. Cold Spring Harbor Laboratory Press, Cold Spring Har-
bor, NY.
28. Schilling, S., C. Wasternack, and H. U. Demuth. 2008. Glutaminyl cyclases
from animals and plants: a case of functionally convergent protein evolution.
Biol. Chem. 389:983–991.
29. Schreckenberger, P. C., M. I. Daneshvar, and D. G. Hollis. 2007. Acineto-
bacter, Achromobacter, Chryseobacterium, Moraxella, and other nonfermen-
tative gram-negative rods, p. 770–802. In P. R. Murray, E. J. Baron, J. H.
Jorgensen, M. L. Landry, and M. A. Pfaller (ed.), Manual of clinical micro-
biology, 9th ed. ASM Press, Washington, DC.
30. Studier, F. W. 2005. Protein production by auto-induction in high density
shaking cultures. Protein Expr. Purif. 41:207–234.
31. Tomatis, P. E., R. M. Rasia, L. Segovia, and A. J. Vila. 2005. Mimicking
natural evolution in metallo--lactamases through second-shell ligand mu-
tations. Proc. Natl. Acad. Sci. USA 102:13761–13766.
32. Walsh, T. R., M. A. Toleman, L. Poirel, and P. Nordmann. 2005. Metallo-
-lactamases: the quiet before the storm? Clin. Microbiol. Rev. 18:306–325.
33. Wang, S. L., W. T. Hsu, T. W. Liang, Y. H. Yen, and C. L. Wang. 2008.
Purification and characterization of three novel keratinolytic metallopro-
teases produced by Chryseobacterium indologenes TKU014 in a shrimp shell
powder medium. Bioresour. Technol. 99:5679–5686.
34. Zeba, B., P. J. Simpore, O. G. Nacoulma, and J. M. Frere. 2005. Identifica-
tion of metallo--lactamase from a clinical isolate at Saint Camille Hospital
Center of Ouagadougou/Burkina Faso. Afr. J. Biotechnol. 4:286–288.
4326 ZEBA ET AL. ANTIMICROB. AGENTS CHEMOTHER.
